Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield Iowa Ingrezza Coverage | Op…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.02.19

    Ingrezza (valbenazine)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.19 alerts

    Get alerted when Policy 05.02.19 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage for Ingrezza (valbenazine) for adults with tardive dyskinesia and chorea associated with Huntington's disease. Coverage requires applicable clinical criteria, supporting documentation, appropriate prescriber involvement, and compliance with quantity limits.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyIngrezza (valbenazine)
    Policy CodePolicy 05.02.19
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot scheduled
    Key ActionSubmit prior authorization requests with the applicable clinical documentation and meet the criteria for the diagnosed condition.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2FDA-approved covered indications
    3 monthsInitial tardive dyskinesia authorization
    6 monthsInitial Huntington's disease chorea authorization
    12 monthsContinuation authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    30/30 days
    Quantity limit

    Coverage Criteria

    Initial therapy - tardive dyskinesia

    Covered for an initial 3-month authorization when ALL of the following are met.

    Initial tardive dyskinesia criteria

    • Core requirements

      • Age: Member is 18 years of age or older.>= 18 years
      • Persistence or inability to modify offending medication

        • Member has persistent tardive dyskinesia symptoms despite a trial of dose reduction, tapering, or discontinuation of the offending medication.
        • Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication.
      • Baseline assessment: Documentation of a baseline structured evaluative tool score has been provided, such as the Abnormal Involuntary Movement Scale (AIMS) or Dyskinesia Identification System: Condensed User Scale (DISCUS).
      • ONE of the following Austedo-related criteria

        • Member has had an inadequate response to a minimum of 3 months of therapy with Austedo (deutetrabenazine).>= 3 months
        • Member has experienced an intolerable adverse event attributed to Austedo.
        • ONE or more Austedo contraindications

          • Huntington's disease and suicidal behavior or untreated or inadequately treated depression.
          • Hepatic impairment.
          • Taking reserpine.

    Initial therapy - Huntington's disease chorea

    Covered for an initial 6-month authorization when ALL of the following are met.

    Initial Huntington's disease chorea criteria

    • Characteristic motor features: Member demonstrates characteristic motor examination features.
    • ONE of the following bases for diagnosis

      • Genetic confirmation: Diagnosis is confirmed by genetic testing, such as an expanded HTT CAG repeat sequence of at least 36.HTT CAG repeat >= 36
      • Family history: Member has a positive family history for Huntington's disease.
    • ONE of the following Austedo-related criteria

    Continuation therapy - tardive dyskinesia

    Covered for a 12-month continuation authorization when the following criterion is met.

    Tardive dyskinesia continuation: Member has moderate to severe tardive dyskinesia and documentation of a positive clinical response to therapy, defined as improvement in the member's structured evaluative tool assessment, such as the Abnormal Involuntary Movement Scale (AIMS) or Dyskinesia Identification System: Condensed User Scale (DISCUS).

    Continuation therapy - Huntington's disease chorea

    Covered for a 12-month continuation authorization when the following criterion is met.

    Huntington's disease chorea continuation: Member is experiencing benefit from therapy for chorea associated with Huntington's disease, evidenced by disease stability or disease improvement.

    Provider Actions and Authorization Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial Ingrezza requests. Coverage may be authorized for tardive dyskinesia or chorea associated with Huntington's disease only when the applicable clinical criteria and documentation requirements are met.

    • Tardive dyskinesia: Authorization may be granted for 3 months for members age 18 or older with moderate to severe tardive dyskinesia related to drug use, persistent despite dose reduction, tapering, or discontinuation of the offending medication, or who are not candidates for such a trial.
    • Huntington's disease chorea: Authorization may be granted for 6 months when characteristic motor examination features are documented and the diagnosis is confirmed by genetic testing (for example, an expanded HTT CAG repeat sequence of at least 36) or supported by a positive family history.
    • A baseline structured evaluative tool assessment must be submitted for tardive dyskinesia, such as the AIMS or DISCUS.
    • The member must meet an Austedo prerequisite pathway: inadequate response to at least 3 months of therapy, an intolerable adverse event, or a contraindication.
    Prior Authorization

    Continuation Prior Authorization

    Policy Background

    Ingrezza (valbenazine) is covered for adults with tardive dyskinesia and for chorea associated with Huntington's disease when applicable prior authorization criteria are met. Initial authorization may be granted for 3 months for tardive dyskinesia and 6 months for Huntington's disease chorea; continuation authorization may be granted for 12 months when documented clinical benefit is demonstrated.

    Initial Therapy Criteria

    Initial tardive dyskinesia

    Initial tardive dyskinesia coverage may be authorized for 3 months when ALL of the following are met.

    Initial tardive dyskinesia criteria

    • Core requirements

      • Member is 18 years of age or older.>= 18 years
      • Persistence or inability to modify offending medication

        • Member has persistent tardive dyskinesia symptoms despite a trial of dose reduction, tapering, or discontinuation of the offending medication.
        • Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication.

    Continuation Therapy Criteria

    Tardive dyskinesia continuation

    Tardive dyskinesia continuation coverage requires documented positive response.

    Tardive dyskinesia response: Member has moderate to severe tardive dyskinesia and documentation of a positive clinical response to therapy, defined as improvement in the member's structured evaluative tool assessment, such as AIMS or DISCUS.

    Huntington's disease chorea continuation

    Huntington's disease chorea continuation coverage requires documented ongoing benefit.

    Huntington's disease chorea response: Member is experiencing benefit from therapy for chorea associated with Huntington's disease, evidenced by disease stability or disease improvement.

    Step Therapy Requirement

    StepTherapyMinimum trialRequirement for Ingrezza
    1Austedo (deutetrabenazine)At least 3 monthsInadequate response or an intolerable adverse event attributed to Austedo. The trial is not required when a listed contraindication applies, including Huntington’s disease with suicidal behavior or untreated or inadequately treated depression, hepatic impairment, reserpine use, MAOI use, or tetrabenazine use.

    Quantity Limits

    Ingrezza capsules
    Quantity limit30 capsules per 30 days
    Ingrezza sprinkle capsules
    Quantity limit30 sprinkle capsules per 30 days
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyIngrezza (valbenazine)
    Policy CodePolicy 05.02.19
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot scheduled
    Key ActionSubmit prior authorization requests with the applicable clinical documentation and meet the criteria for the diagnosed condition.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Authorization RequirementsPolicy BackgroundInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy RequirementQuantity Limits
    Taking a monoamine oxidase inhibitor (MAOI).
  1. Taking tetrabenazine.
    • Member has had an inadequate response to a minimum of 3 months of therapy with Austedo (deutetrabenazine).>= 3 months
    • Member has experienced an intolerable adverse event attributed to Austedo.
    • ONE or more Austedo contraindications

      • Huntington's disease and suicidal behavior or untreated or inadequately treated depression.
      • Hepatic impairment.
      • Taking reserpine.
      • Taking a monoamine oxidase inhibitor (MAOI).
      • Taking tetrabenazine.

    Continuation authorization may be granted for 12 months when the submitted records demonstrate that the member is benefiting from Ingrezza therapy.

    • Tardive dyskinesia: Document a positive clinical response, including improvement in a structured evaluative tool assessment such as AIMS or DISCUS.
    • Huntington's disease chorea: Document benefit through disease stability or improvement.

    Unsupported block type: step_therapy

    Documentation Required

    Initial Request Documentation

    Submit chart notes or medical records supporting the initial clinical criteria and the applicable diagnosis.

    • Clinical manifestations of tardive dyskinesia or characteristic motor examination features for Huntington's disease chorea.
    • Baseline structured evaluative tool assessment, such as AIMS or DISCUS, when requesting treatment for tardive dyskinesia.
    • Treatment outcomes, intolerable adverse events, or contraindications to Austedo.
    Documentation Required

    Continuation Request Documentation

    Submit current chart notes or medical records demonstrating positive clinical response and ongoing benefit from Ingrezza.

    • For tardive dyskinesia, document improvement in signs and symptoms and improvement in the structured evaluative tool assessment, such as AIMS or DISCUS.
    • For Huntington's disease chorea, document disease stability or improvement.
    Documentation Required

    Prescriber Specialty Documentation

    Ingrezza must be prescribed by or in consultation with an appropriately qualified specialist for the requested indication.

    • Tardive dyskinesia: Neurologist, psychiatrist, or specialist in the treatment of tardive dyskinesia.
    • Huntington's disease chorea: Neurologist or specialist in the treatment of chorea associated with Huntington's disease.
    Denial Risk

    Tardive Dyskinesia Criteria Not Met

    An initial tardive dyskinesia request should be denied when the member does not meet all applicable criteria for coverage.

    • Member is younger than 18 years of age.
    • Symptoms are not moderate to severe or are not persistent despite dose reduction, tapering, or discontinuation of the offending medication, and the member is a candidate for such a trial.
    • Required baseline structured evaluative tool documentation is absent.
    • The member does not have an inadequate response to at least 3 months of Austedo, an intolerable Austedo-related adverse event, or a qualifying Austedo contraindication.
    Denial Risk

    Huntington's Disease Chorea Criteria Not Met

    An initial Huntington's disease chorea request should be denied when the member does not meet all applicable criteria for coverage.

    • Characteristic motor examination features are not documented.
    • The diagnosis is not confirmed by qualifying genetic testing and there is no positive family history for Huntington's disease.
    • The member does not have an inadequate response to at least 3 months of Austedo, an intolerable Austedo-related adverse event, or a qualifying Austedo contraindication.
    Denial Risk

    Insufficient Response for Continuation

    Continuation authorization should be denied when the records do not demonstrate meaningful ongoing benefit from Ingrezza.

    • For tardive dyskinesia, deny when there is no documented positive clinical response or improvement in the structured evaluative tool assessment.
    • For Huntington's disease chorea, deny when disease stability or improvement is not documented.
    • A 12-month continuation authorization is not supported without current clinical records demonstrating ongoing benefit.
    Denial Risk

    Benefit or Contract Exclusion

    Coverage is subject to the member's applicable contract. Verify that the benefit exists and that no exclusions, limitations, or exceptions apply before submitting or approving authorization.

    • Benefits may vary by contract and individual member benefits must be verified.
    • Wellmark determines medical necessity only when the benefit exists and no contract exclusion applies.
    • This policy may not apply to the Federal Employee Program; FEP benefits are determined by that program.
  2. Documentation of a baseline structured evaluative tool score has been provided, such as AIMS or DISCUS.
  3. ONE of the following Austedo-related criteria

    • Inadequate response to a minimum of 3 months of therapy with Austedo (deutetrabenazine).>= 3 months
    • An intolerable adverse event attributed to Austedo occurred.
    • ONE or more Austedo contraindications

      • Huntington's disease and suicidal behavior or untreated or inadequately treated depression.
      • Hepatic impairment.
      • Taking reserpine.
      • Taking a monoamine oxidase inhibitor (MAOI).
      • Taking tetrabenazine.
  4. Initial Huntington's disease chorea

    Initial Huntington's disease chorea coverage may be authorized for 6 months when ALL of the following are met.

    Initial Huntington's disease chorea criteria

    • Member demonstrates characteristic motor examination features.
    • ONE of the following bases for diagnosis

      • Diagnosis is confirmed by genetic testing, such as an expanded HTT CAG repeat sequence of at least 36.HTT CAG repeat >= 36
      • Member has a positive family history for Huntington's disease.
    • ONE of the following Austedo-related criteria

      • Inadequate response to a minimum of 3 months of therapy with Austedo (deutetrabenazine).>= 3 months
      • An intolerable adverse event attributed to Austedo occurred.
      • ONE or more Austedo contraindications

        • Huntington's disease and suicidal behavior or untreated or inadequately treated depression.
        • Hepatic impairment.
        • Taking reserpine.
        • Taking a monoamine oxidase inhibitor (MAOI).
        • Taking tetrabenazine.